Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Stephen Robb¹  Jessica Mann¹  R. Scott Wright²  Daniel Cournoyer³  Marie‐Claude Guertin³  Valérie Duchatelle⁴  Thibaut Petroni⁴  Catherine Gebhard⁴  Barbara E. Stähli⁴  Philippe L. L'Allier⁴  Jean‐François Tanguay⁴  Jean‐Claude Tardif⁴ 

[1] Hoffmann‐La Roche, Basel, Switzerland;Mayo Clinic, Rochester, MN;Montreal Health Innovations Coordinating Center (MHICC), Montreal, Canada;Montreal Heart Institute, Université de Montréal, Montreal, Canada;

关键词: acute coronary syndrome;    inflammation;    myocardial infarction;    percutaneous coronary intervention;    thrombosis;   

DOI  :  10.1161/JAHA.116.004255

来源: DOAJ

【 摘 要 】

BackgroundThe Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial Infarction (SELECT‐ACS) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P‐selectin, on periprocedural myocardial damage. This study evaluated the effect of inclacumab on myocardial damage according to varying time intervals between study drug infusion and percutaneous coronary intervention (PCI). Methods and ResultsPatients (n=544) enrolled in the SELECT‐ACS trial and randomized to receive 1 infusion of placebo or inclacumab (5 or 20 mg/kg, administered between 1 and 24 hours before PCI) were divided according to the time interval between study drug infusion and PCI. The primary end point was the change in troponin I from baseline at 16 and 24 hours after PCI. In patients receiving inclacumab 20 mg/kg with a short (less than median) time interval between infusion and PCI, placebo‐adjusted geometric mean percent changes in troponin I, creatine kinase–myocardial band, and peak troponin I at 24 hours were −45.6% (P=0.005), −30.7% (P=0.01), and −37.3% (P=0.02), respectively. No significant changes were observed in patients with a long (greater than median) time interval between infusion and PCI. Placebo‐adjusted geometric mean percent changes in troponin I and creatine kinase–myocardial band were −43.5% (P=0.02) and −26.0% (P=0.07), respectively, when inclacumab 20 mg/kg was administered between 1 and 3 hours before PCI, whereas the drug had no effect with longer intervals. ConclusionsInclacumab 20 mg/kg significantly reduces myocardial damage after PCI in patients with non–ST‐segment elevation myocardial infarction, and benefits are larger when the infusion is administered <3 hours before PCI. Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01327183.

【 授权许可】

Unknown